A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes
about
Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acidAn overview of epigenetics and chemopreventionHistone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I studyEpigenetics of cervical cancer. An overview and therapeutic perspectivesAntineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines.Aberrant DNA methylation in cervical carcinogenesisThe role of DNA methylation in aging, rejuvenation, and age-related diseaseGenome-wide mapping of DNA methylation in the human malaria parasite Plasmodium falciparumNoncoding RNAs in Tumor Epithelial-to-Mesenchymal TransitionAssociation of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancerHydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trialDNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cellsA proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.DNA methyltransferases: a novel target for prevention and therapy.A higher degree of expression of DNA methyl transferase 1 in cervical cancer is associated with poor survival outcome.A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results.Identification of kazinol Q, a natural product from Formosan plants, as an inhibitor of DNA methyltransferase.DNA demethylating antineoplastic strategies: a comparative point of viewInduction of Tet3-dependent Epigenetic Remodeling by Low-dose Hydralazine Attenuates Progression of Chronic Kidney DiseaseEpigenetic therapy for breast cancer.The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical studyEpigenetic mechanisms in virus-induced tumorigenesis.p16INK4a gene promoter hypermethylation in mucosa as a prognostic factor for patients with colorectal cancer.Sequential gene promoter methylation during HPV-induced cervical carcinogenesisA Phase I Protocol of Hydralazine and Valproic Acid in Advanced, Previously Treated Solid Cancers.Genetic and epigenetic alterations in breast cancer: what are the perspectives for clinical practice?DNA methylation as clinically useful biomarkers-light at the end of the tunnelRosiglitazone prevents the progression of preinvasive lung cancer in a murine model.Molecular epigenetics in the management of ovarian cancer: are we investigating a rational clinical promise?The application of delivery systems for DNA methyltransferase inhibitors.Emerging promise of epigenetics and DNA methylation for the diagnosis and management of women's cancers.DNA methylation and cancer diagnosis.Epigenetics and cervical cancer: from pathogenesis to therapy.Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer.Epigenetic alterations in gastric cancer (Review).Developmental DNA methyltransferase inhibitors in the treatment of gynecologic cancers.DNA methyltransferase inhibitors: an updated patent review (2012-2015).Anti-neoplastic properties of hydralazine in prostate cancer.Hydralazine-induced promoter demethylation enhances sarcoplasmic reticulum Ca2+ -ATPase and calcium homeostasis in cardiac myocytes.The antihypertensive drug hydralazine activates the intrinsic pathway of apoptosis and causes DNA damage in leukemic T cells.
P2860
Q24288944-5F4DAEEF-25E1-4A62-866A-0DE5DD26EB0BQ24623823-4D88398D-6D68-41C7-98AB-F493F9FDCEDCQ24810933-E8C50C0C-1698-4CF4-9504-1A2F22DBFC2AQ24812104-B2EC40C4-D973-493B-B6CA-309BB8AB8393Q25255934-BEC2127D-CFDA-4301-B47B-9A4A608E9A04Q26830289-C4C15DC3-84FB-4F15-892B-BB74BA801C74Q27025194-98A2DCB4-A213-4E58-9907-AC56CC550087Q27972932-92E88D84-2CEB-43E2-9FAA-6547ABDAEE80Q28080346-54281872-0D31-43CC-A20B-8F2EFFA8207EQ28253304-3569410B-CFBB-4E6D-B6F7-62984AEF59EFQ28294892-37D19732-C180-40BB-85E5-A19CB45FEECAQ28481440-AE37B4B5-23B2-4BBA-8D48-67F47A0D8765Q33267359-5A23FC34-070E-4569-AB91-29CD947A7E65Q33579896-8A96E82F-C672-4259-A7EE-111985DC0194Q33812527-D7CC7A32-10DA-4142-B6F8-B9D022E7E198Q34142430-20A5BFDC-56DC-4F5D-BC11-AD58A4D202F8Q34601752-6DA28329-0B4B-48E3-AB22-CB171971515FQ34972245-FCBDAAA9-3603-4005-8DB0-DD0E94ED57DBQ35110633-D85EBE4E-0B56-45C5-946C-055EAF50F82BQ35162148-21484CFB-990A-4159-A043-8DE58948E9AEQ35674823-72F59050-9122-4E10-8B96-72094EC503F3Q36001887-694B3404-AF04-4E15-8CA4-F41893834DD6Q36556548-F46EBA00-C869-4A05-94EB-85DECBF3E8EFQ36610652-A4C3EE7E-A9A6-489A-A4B0-BD7BD4B46233Q36689831-D114DE8A-DFAC-46FA-8353-BD61577298B2Q37025333-BEB1707F-DE9F-479D-B583-B740E3E108A3Q37148677-50E43D5C-9FA6-42E8-A09A-26D191CFD341Q37472163-0B797CED-C410-474A-8D10-C16C611CB63EQ37702543-5C808F87-ECC1-4E33-B487-8E72CE10CF4FQ37911496-86B336D8-508C-4F70-B908-D83DA910B250Q37962013-52658A72-1F0C-45D8-9DF0-38AD609F6319Q38123094-57B57BB5-0FD4-4F65-B568-AA4FFB2165F8Q38189740-B7D25D08-876F-4DF0-B444-B2DF0E6A0E90Q38242979-304B06B0-D774-436B-871D-E7B1B83A1E86Q38495706-86DE1F1B-C9CF-4398-A61B-9411E744A13EQ38630962-A1279F0A-A615-4C87-9E96-F10433F51CAFQ38885370-238D0EAC-BABD-4B26-9832-204C55FA5BA0Q38998403-B6464C97-FA44-41C6-ACE3-766BEF9427FDQ39508627-B7BBE795-AC1B-4FD4-B771-F938A9B65F7DQ40996500-D368E752-DA39-45B3-ADBB-BE3BB2338566
P2860
A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes
description
2005 nî lūn-bûn
@nan
2005 թուականին հրատարակուած գիտական յօդուած
@hyw
2005 թվականին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
A phase I study of hydralazine ...... sion of tumor suppressor genes
@ast
A phase I study of hydralazine ...... sion of tumor suppressor genes
@en
A phase I study of hydralazine ...... sion of tumor suppressor genes
@nl
type
label
A phase I study of hydralazine ...... sion of tumor suppressor genes
@ast
A phase I study of hydralazine ...... sion of tumor suppressor genes
@en
A phase I study of hydralazine ...... sion of tumor suppressor genes
@nl
prefLabel
A phase I study of hydralazine ...... sion of tumor suppressor genes
@ast
A phase I study of hydralazine ...... sion of tumor suppressor genes
@en
A phase I study of hydralazine ...... sion of tumor suppressor genes
@nl
P2093
P2860
P3181
P356
P1433
P1476
A phase I study of hydralazine ...... sion of tumor suppressor genes
@en
P2093
Alfonso Duenas-González
Alma Chavez-Blanco
Alma Revilla-Vazquez
Blanca Segura-Pacheco
Catalina Trejo-Becerril
Enrique Angeles
Enrique Perez-Cardenas
Gustavo Cabrera
Jose Chanona-Vilchis
Karina Sandoval
P2860
P2888
P3181
P356
10.1186/1471-2407-5-44
P407
P577
2005-01-01T00:00:00Z
P5875
P6179
1001955909